TABLE II-A. Representative list of up-regulated genes in biliary epithelial cells of PBC  in comparison with levels in normal subjects

TABLE II-C. Representative list of up-regulated genes in biliary epithelial cells of PBC  in comparison with levels in chronic hepatitis C

Table 1: Genes undergoing most striking up-regulation at 15  30  120 and 240 minutes post TGF-?1 exposure.

Table 2: Genes undergoing most striking down-regulation at 15  30  120 and 240 minutes post TGF-?1 exposure.

Table 1. Genes differentially expressed by MAK-KR overexpression in LNCaP cells

Table 1b. Differentially expressed genes: down-regulated

Table 2. Differentially expressed genes: cDNA

Table 1a. Differentially expressed genes: up-regulated

Table 2. Oncogenes and tumor suppressors inhibited by RAR ligands

Table 3. Oncogenes and tumor suppressors induced by RAR ligands

Table 2 Downregulated genes in 3-month-old HBV transgenic mice.

Table 1 Upregulated genes in 3-month-old HBV transgenic mice.

Supplementary Table I. List of 155 genes used for cluster analysis-155 genes for which expression differed in primary sensitive and resistant tumors

Table III. Predictor set of 43 genes differentially expressed between ovarian cancer patients who displayed sensitivity (TTR >22 months) or resistance (TTR ?22 months) to first-line chemotherapy.

Figure 5. Training dataset samples dendrogram clustered on BCMP11/ABCC11 centroid genes

Table 2 Genes upregulated and associated with group II (Malignant cluster) as determined by hierarchical clustering

Table 2 Genes upregulated and associated with group I (benign cluster) as determined by hierarchical clustering

Table 3 Identification of genes that distinguish among benign  borderline and malignant ovarian tumours by prediction analysis of microarrays

Table 2. Differentially expressed genes in MDA-MB-435HM and MDA-MB-435LM cell lines revealed by cDNA microarray analysis

Table 2. Genes more expressed in tumours from patients in the sub-group of survivors compared with the remaining tumours  with at least two-fold change and adjusted P-value <0.05  and in tumours from all survivors compared with tumours from deceased patients with adjusted P-value <0.2